Dr. James D'olimpio
Hematology & Oncology (Hematology & Oncology Physician)
450 Lakeville Road, The Monter Cancer Center
Lake Success, NY 11042
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 139910
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $369 in total to this clinician.
| Janssen Research & Development, LLC | $150 |
|---|---|
| Merck Sharp & Dohme LLC | $147 |
| Beigene Switzerland GmbH | $71.84 |
| Food and Beverage | $369 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 64 industry-funded studies in 2025, from 21 companies. The companies reported $2,605,235 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo Inc. · Recruiting · NCT06330064 - Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Beone Medicines Ltd. · Completed · NCT04116437 - A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862 - Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
E.r. Squibb & Sons, L.l.c. · Completed · NCT01996865 - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcH…
Merck Sharp & Dohme LLC - A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT06660654
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.